maia biotechnology, inc. is a targeted therapy, immune-oncology company, focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. a privately-held company based in chicago, maia is led by a passionate, principled and highly experienced management team with significant drug development experience, committed to advancing promising agents into trials in humans clinical trials. maia’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. maia controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. maia’s business model involves placing drug candidates in their own dedicated, r&d focused subsidiary company, which is supported by the common infrastru